Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its ...

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to treat type 2 diabetes. Novo's drugs Ozempic and Wegovy are household names ...

You'll probably recognize their names after seeing them in the news or across social media: Ozempic and Wegovy (made by Novo ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the ...

In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...